Veru Inc. (VERU) Stock Price & Analysis
Veru Inc. (VERU) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $2.11 (-8.66%), as of the Nov 19, 2026 trading session; market cap $36.0M.
Educational signal · not a buy or sell recommendation · How to read this
Veru Inc. · VERU · NASDAQ
Veru Inc. is an oncology biopharmaceutical company focused on developing medicines for managing cancers and other diseases.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Veru (VERU)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and an expensive valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Quiet.
Free cash flow yield is the main valuation drag relative to sector peers.
- EPS beat 1 of the last 4 reports
- Altman Z -11.77 · Piotroski F 1
- ROE -64.5% · ROA -54.0% · current ratio 4.42
Holding back: a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.11 | |
| Change on the day | -8.66% | |
| 52-week range | $2.04 – $7.33 | |
| Market capitalisation | $36.0M | — |
| Shares traded on the day | 76.9K |
Price & events
Other perspectives
Council score for Veru (VERU): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Englander-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens disagrees with the Valuation pillar (Bubble, 17 of 100): it reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Veru (VERU), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Veru Inc. (VERU) is listed on NASDAQ. It employs 20 people and is led by Mitchell S. Steiner. The market values it at $36.0M.
What do the latest results show for Veru (VERU)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
What are the financial strengths and risks for Veru (VERU)?
Short answer · as of
What is holding it back is a rich price, soft growth. The distress and quality screens read Altman Z -11.77 · Piotroski F 1. Trailing ratios: ROE -64.5% · ROA -54.0% · current ratio 4.42.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -11.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-64.5%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Veru (VERU)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.67M · EPS -0.81 · 3 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for VERU.
Checked against the records this page reads, on the dates shown above.
How does Veru compare with its peers?
Short answer
Veru's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| Veru (VERU) — this page | $2.11 | $36.0M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $2.67M
- EPS estimate
- $-0.81
Measured against a quoted price of $2.11 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 8
- Purchases
- 1
- Sales
- 0
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VERU in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VERU in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Veru (VERU)?
- Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
- Veru Inc. Chief Scientific Officer to Present at ObesityWeek 2026
- Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026
- Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
Investor Questions: VERU Stock
These answers are editorial: 1 of these 9 answers is drawn from the VERU research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for VERU?
VERU carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is VERU a good stock to buy?
Stock Expert AI does not rate VERU buy, sell or hold. Veru Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VERU stock price today?
The last price recorded for Veru Inc. (VERU), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for VERU?
Veru Inc. faces several key risks inherent to the biotechnology industry. Clinical trial risk is paramount, as the failure of Enobosarm or Sabizabulin to demonstrate efficacy or safety in Phase III trials would significantly impact the company's value.
What are the key factors to evaluate for VERU?
Veru Inc. (VERU) holds a MoonshotScore in the low range. Prostate cancer is a significant market, and there is a need for new treatments that can overcome resistance to existing therapies. Not financial advice.
How frequently does VERU data refresh on this page?
VERU's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VERU's recent stock price performance?
Veru Inc. (VERU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of drug candidates targeting unmet needs in oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VERU overvalued or undervalued right now?
Veru Inc. (VERU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of VERU?
Fractional-share availability for Veru Inc. (VERU) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 7 from Financial Modeling Prep (FMP), 8 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com